Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials.

@article{Goss2013ModafinilAT,
  title={Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials.},
  author={Alexander J. Goss and Muzaffer Kaşer and Sergi G. Costafreda and Barbara Jacquelyn Sahakian and Cynthia H. Y. Fu},
  journal={The Journal of clinical psychiatry},
  year={2013},
  volume={74 11},
  pages={
          1101-7
        }
}
OBJECTIVE Current pharmacologic treatments for a depressive episode in unipolar major depressive disorder (MDD) and bipolar depression are limited by low rates of remission. [...] Key MethodDATA SOURCES MEDLINE/PubMed, PsycINFO, 1980-April 2013 were searched using the following terms: (modafinil or armodafinil) and (depressi* or depressed or major depressive disorder or major depression or unipolar or bipolar or dysthymi*).Expand
View on PubMed
gwern.net
88 Citations
Highly Influential Citations
4
Background Citations
21
Methods Citations
5
Results Citations
3

88 Citations

Citation Type

Citation Type

Adjunctive treatment with psychostimulants and stimulant-like drugs for resistant bipolar depression: a systematic review and meta-analysis.
TLDR
Treatment guidelines should be revised to include these medications earlier in the therapeutic algorithm for resistant acute bipolar depression patients, as LDX, modafinil, and armodaf inil seem to offer a reasonably well-tolerated and safe treatment in resistant bipolar depression. Expand
Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence
TLDR
Off-label augmentation agents (administered in addition to an antidepressant, without FDA approval for treatment of MDD) were identified and evaluated regarding their efficacy using levels of evidence, and five substances were shown to be clinically effective in high evidence studies. Expand
Optimized Treatment Strategy for Depressive Disorder.
  • Peijun Chen
  • Medicine
  • Advances in experimental medicine and biology
  • 2019
TLDR
Optimizing pharmacotherapy consists of switching to different agents, combination with different antidepressants, or augmentation with different class of psychotropic medications, and the latter is preferred. Expand
Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study.
TLDR
Overall, AA yielded potentially beneficial clinical outcomes compared to SW and the tolerability profiles were comparable between the two groups. Expand
Treatment of neurocognitive symptoms in unipolar depression: A systematic review and future perspectives.
TLDR
Current evidence is not sufficient to widely recommend the use of procognitive treatments in MDD although promising results are coming to light. Expand
Managing inadequate antidepressant response in depressive illness.
TLDR
Depression frequently fails to respond to initial treatment and strategies with the strongest support are antidepressant augmentation with lithium or second generation antipsychotics and adding cognitive behavioural treatment. Expand
Modafinil Moderates the Relationship Between Cancer-Related Fatigue and Depression in 541 Patients Receiving Chemotherapy
TLDR
Modafinil differentially impacts depression based on a patient’s level of fatigue and reduced depressive symptoms only in those with extreme fatigue, and this effect may be driven by increases in positive affective symptoms. Expand
Cognition as a target in major depression: New developments
TLDR
There are a number of promising new therapies, pharmacological agents or complementary medicines, but data are just emerging that should prove effective in improving specific cognitive domains and functioning in MDD, while ruling out pseudospecificity. Expand
Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
TLDR
The evidence found supports adding or switching to another antidepressant from a different class is an effective strategy in more severe MDD after failure to an initial antidepressant trial, and some augmentation strategies and antidepressant combinations should be considered. Expand
The role of methylphenidate in depression
Abstract Introduction: Depression is a burdening disease state where up to 30% of individuals do not respond to first-line treatment. Adjunctive use of psychostimulants has been investigated for the… Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
Psychostimulants in moderate to severe affective disorder: A systematic review of randomized controlled trials
TLDR
Clearly larger well designed placebo-controlled studies with longer follow-up accompanied by evaluations of tolerance/dependence are warranted before psychostimulants can be recommended in routine clinical practice for the treatment of MDD. Expand
Use of adjunctive stimulants in adult bipolar depression.
TLDR
An updated perspective on the use of stimulants and stimulant-like medications in adult bipolar depression is provided, considering not only recent randomized controlled trials, but also open naturalistic studies, in order to clarify the strengths and limitations of using these agents. Expand
A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
TLDR
Modafinil is a well-tolerated and potentially effective augmenting agent for SSRI partial responders with fatigue and sleepiness despite selective serotonin reuptake inhibitor (SSRI) monotherapy. Expand
Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness.
TLDR
Results of this pooled analysis provide further evidence suggesting that modafinil is an effective and well-tolerated augmentation therapy for partial responders to SSRI therapy, particularly when patients continue to experience fatigue and excessive sleepiness. Expand
Open-label study of adjunct modafinil for the treatment of patients with fatigue, sleepiness, and major depression treated with selective serotonin reuptake inhibitors
TLDR
Results of this preliminary, open-label trial suggest that modafinil may be effective in augmenting ongoing SSRI treatment for a portion of patients with major depression who have residual fatigue and sleepiness. Expand
Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.
TLDR
Modafinil rapidly improved fatigue and daytime wakefulness, with significantly greater mean improvements from baseline than placebo in fatigue (FSS) scores at week 2 and sleepiness (ESS) Scores at week 1; the differences between modaf inil and placebo at week 6 were not statistically significant. Expand
Modafinil Augmentation of SSRI Therapy in Patients with Major Depressive Disorder and Excessive Sleepiness and Fatigue: A 12-Week, Open-label, Extension Study
TLDR
Twelve weeks of modafinil augmentation relieved excessive sleepiness, reduced fatigue, and improved patients' overall clinical condition, including mood. Expand
A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression.
TLDR
These data suggest that adjunctive modafinil at doses of 100-200 mg a day may improve depressive symptoms in patients with bipolar disorder. Expand
Modafinil for Remitted Bipolar Depression with Hypersomnia
TLDR
Modafinil may be a well-tolerated and effective alternative to conventional stimulants in the treatment of hypersomnia, especially in bipolar disorder, where there is considerable risk of switch to mania with stimulant medications. Expand
Modafinil augmentation of antidepressant treatment in depression.
TLDR
Modafinil appears to be a drug with promise as an augmenter of antidepressants, especially in patients with residual tiredness or fatigue, and is a particularly attractive alternative to other stimulants because of its low abuse potential and Schedule IV status. Expand
...
1
2
3
4
...